Ebos chief executive John Cullity said multiples these days tend to be between seven and nine times operating earnings, up from 5.5 times to six times five years ago.
Ebos Group remains confident it can continue its pace of double-digit growth.
Increasing digitisation and developing technologies, such as artificial intelligence, should aid its radiology businesses in going global.
The NZ medicinal cannabis sector could be worth $2 billion by 2030, driven by the use of low dosage products, but that will require a change in the rules.